Ovid Therapeutics Inc OVID
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-05-05 |
| Shares Out. | 186,640,000 |
| Website | ovidrx.com/ ↗ |
| Phone | 12127764381 |
| Employees | 23 |
| Net Income | -$17.0M |
| Total Assets | $225.6M |
| Total Liabilities | $27.4M |
| Equity | $198.3M |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ovid Therapeutics Inc is a publicly traded company under the ticker symbol OVID on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)